Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

@article{Zago2012NeutralizationOS,
  title={Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.},
  author={Wagner Zago and Manuel Buttini and Thomas A. Comery and Christopher Nishioka and Shyra J. Gardai and Peter Seubert and Dora Games and Fr{\'e}d{\'e}rique Bard and D. S. Schenk and Gene G. Kinney},
  journal={The Journal of neuroscience : the official journal of the Society for Neuroscience},
  year={2012},
  volume={32 8},
  pages={
          2696-702
        }
}
Several anti-amyloid β (Aβ) antibodies are under evaluation for the treatment of Alzheimer's disease (AD). Clinical studies using the N-terminal-directed anti-Aβ antibody bapineuzumab have demonstrated reduced brain PET-Pittsburg-B signals, suggesting the reduction of Aβ plaques, and reduced levels of total and phosphorylated tau protein in the CSF of treated AD patients. Preclinical studies using 3D6 (the murine form of bapineuzumab) have demonstrated resolution of Aβ plaque and vascular… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Similar Papers

Loading similar papers…